Background: The value of allogeneic hematopoietic cell transplantation (alloHCT) as postremission treatment is not well defined for patients with intermediate-risk acute myeloid leukemia (AML) without FLT3-ITD, biallelic CEBPA-, or NPM1 mutations (here referred to as NPM1 mut-neg /CEBPA dm-neg /FLT3-ITD neg AML) in first complete remission (CR1).
Introduction
In patients with acute myeloid leukemia (AML), the chance of achieving and maintaining a complete remission with postremission chemotherapy (PR-CT) is determined by recurrent genetic abnormalities. These designate risk groups of patients for whom allogeneic hematopoietic cell transplantation (alloHCT) in first complete remission (CR1) should be considered [1] together with the response to induction chemotherapy (ICT).
Mutations in the nucleophosmin gene (NPM1 mut ) and biallelic mutations in the CCAAT/enhancer binding protein a gene (CEBPA dm ) in the presence of a normal karyotype confer a favorable prognosis [1, 2] . Therefore, AMLs with CEBPA dm or NPM1 mut without concomitant FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) are listed as distinct entities in the 2016 revision of the WHO-classification and are grouped into the favorable genetic risk group according to the European Leukemia Net (ELN) [1, 3] . Procedure-related mortality after alloHCT was shown to counterbalance the beneficial effect on disease control [2, 4] . Significantly improved relapse-free survival (RFS) but not overall survival (OS) after alloHCT in CR1 compared with PR-CT has been observed in multiple studies [2, 5, 6] . This pattern of outcomes in favorable risk AML patients can partly be explained by cross-over effects of patients who received alloHCT at relapse. Internal tandem duplications in the juxtamembrane domain coding region of the FLT3 gene result in constitutive activation of this receptor tyrosine kinase, which controls cell proliferation and differentiation. Patients with FLT3-ITD AML have an aggressive clinical course depending on the ratio of mutated to wild-type allele [5, 7] . Patients with a high ratio more often present with hyperleukocytosis, and have a higher risk of induction failure (IF) [7] . Although the majority of patients with FLT3-ITD positive AML achieve CR1 with intensive ICT, 49%-89% relapse within 3-5 years even after several cycles of PR-CT [6, 7] . In patients with FLT3-ITD positive AML, alloHCT reduced the risk of relapse and improved RFS and OS in several independent registry-based studies compared with PR-CT [6, 8, 9] .
For patients with intermediate risk
, the risk-benefit ratio for alloHCT in CR1 is poorly defined. This subgroup has been labeled 'triple-negative' AML by some groups [2, 10, 11] . Published retrospective data on the outcome of patients within this group after alloHCT is limited and controversial. While Schlenk et al. reported poor outcomes, analyzing the FLT3-ITD positive and the triple-negative group combined, Ahn et al. and Schmid et al. reported a favorable OS after alloHCT for the triplenegative group [2, 10, 11] . Data comparing the outcomes of alloHCT and PR-CT for NPM1 
Patients and methods

Study design
We carried out a retrospective analysis on the value of alloHCT in patients with AML who were enrolled into the prospective, randomized AML96 or AML2003 trials (NCT00180115 and NCT00180102) of the Study Alliance Leukemia (SAL). Selection criteria were NPM1 wt and absence of both FLT3-ITD and CEPBA dm , a karyotype not defined as 'favorable' or 'adverse' according to ELN criteria [1] , and documented CR1.
In total, 1179 patients aged 16-60 years with newly diagnosed AML were enrolled into the AML2003 trial. The aim of the study, recruiting between 2003 and 2009, was to compare consolidation therapies [14, 15] . In the genetic subgroup of interest, alloHCT was offered to all patients with an HLA-identical sibling donor in CR1, irrespective of the randomization into the control or early alloHCT arm (cf. supplementary Figure S1 , available at Annals of Oncology online). In the latter, patients with poor early bone marrow blast (BMB) clearance, i.e. >10% BMB on d15 after first ICT, were scheduled for HLA-compatible-related or unrelated alloHCT in aplasia after first or second ICT.
Into the AML 96 trial 933 patients aged 15-60 years with newly diagnosed AML were enrolled [16] . AlloHCT was offered to patients younger than 55 years with an HLA-identical sibling donor as a second consolidation.
In both trials myeloablative conditioning (MAC) regimes, defined as a cumulative dose of Busulfan >8 mg/kg bodyweight or 8 Gy total body irradiation, or reduced intensity conditioning (RIC) were applied, depending on patient age and the performance status.
Both trials included patients with de novo AML, secondary AML (sAML) following a myelodysplastic syndrome, and therapy-related myeloid neoplasm (tMN). The trials were approved by the local ethics committees and conducted in compliance with the declaration of Helsinki. All patients gave informed consent for additional analyses using medical data and genetic information.
Cytogenetic and molecular analyses
Standard methods for molecular analyses (fluorescence in situ hybridization, chromosome banding) were utilized in both trials. Screening for FLT3-ITD, NPM1, and CEBPA was carried out for patients with intermediate risk karyotypes using PCR and sequencing techniques as published earlier [5, 17] . The analyses were carried out in a central reference laboratory.
Statistical analysis
Our primary objective was to determine the impact of alloHCT in CR1 on OS and RFS. The cumulative incidence of relapse (CIR) and nonrelapse mortality (NRM) were analyzed as secondary end points. The AML2003 study allowed for a biological assignment and comparison of patients with or without sibling donor, since this information was collected at study enrollment. No baseline information on donor availability was collected in the AML96 study.
Kaplan-Meier estimates were used for plots and to report survival probabilities for defined times. Multivariate Cox models were fitted to analyze the impact of alloHCT as a time-dependent covariate. Age, gender, white blood count, lactate dehydrogenase, AML type (de novo, sAML, tMN) and Eastern Cooperative Oncology Group (ECOG) performance status at diagnosis were selected as adjusting covariates according to SAL standards.
Data from both trials were included for complementary as-treated analyses. For those, alloHCT and PR-CT were entered as time-dependent covariates into extended Cox regression models. As the average time from CR1 to alloHCT was 1 month, a 1-month landmark was set for the Simon-Makuch plots for RFS. For OS, a 3-month landmark was set as the average time from study inclusion to alloHCT was 3 months.
A P value <0.05 was considered as statistically significant. Follow-up data were administratively censored after 6 years. Statistical analyses were carried out with R V3.1.3 [18] . Table 1 . For donor versus no donor analyses data on 276 patients with donor status information at diagnosis who were treated in the AML2003 study were available. For time-dependent analyses of postremission therapies in CR1 data on 302 patients from both trials were available.
Results
Patient characteristics and outcomes
After administrative censoring, the median follow-up was 6 years. For the whole cohort, median OS from study enrollment was 29 (95% CI 23-45) months. Median RFS from CR1 was 17 (95% CI 14-25) months.
Donor versus no-donor analysis in AML2003 study
Out of 276 patients with NPM1 mut-neg /CEBPA dm-neg /FLT3-ITD neg AML, an HLA-identical sibling donor was available for 83 patients. On d15 counted from the first ICT, 123 patients (44%) had >10% BMB, and 36% had IF during protocol treatment.
At baseline, patients with and without an HLA-identical donor were randomly assigned to the control (n ¼ 139) and the early alloHCT arm (n ¼ 137), thereby building four treatment groups with slightly different transplant strategies (cf. supplementary Figure  S1 , available at Annals of Oncology online). Kaplan-Meier survival plots for RFS and OS for all four groups (donor versus no-donor arm, early alloHCT arm versus control arm) are shown in Figure 1 .
Impact of donor availability in the control arm
We first compared the impact of donor availability in the control arm of the AML2003 trial. After adjustment for baseline risk factors, patients with a sibling donor had a significantly better RFS (HR 0.5, 95% CI 0.3-0.9; P ¼ 0.02) and a trend (HR 0.6; 95% CI 0.3-1.1; P ¼ 0.08) toward better OS. The percentages of patients who received alloHCT in CR1 were 58% for patients with a sibling donor versus 10% for those without a sibling donor. The probability of RFS at 5 years from CR1 was 49% (95% CI 35% to 68%) for sibling donor patients compared with 26% (95% CI 18% to 37%) for no-donor patients ( Figure 1A) . At 5 years from study enrollment, OS of patients with sibling donor was 59% (95% CI 45% to 78%) compared with 42% (95% CI 33% to 53%) without ( Figure 1B) .
Impact of study treatment
The concept of early alloHCT including early unrelated donor transplantation was primarily successful in the group of patients with poor d15 BMB clearance and IF (supplementary Figure S1 , available at Annals of Oncology online). When analyzed according to the intent-to-treat by randomization, the HR for the early alloHCT-versus control arm was 0.5 (95% CI 0.3-1.0, P ¼ 0.06) for both end points, OS and RFS.
Time-dependent analysis of postremission therapies in CR1
We carried out complementary analyses to compare the administered consolidation therapy of patients who had achieved CR1 in /FLT3-ITD neg AML, we excluded 195 patients due to IF on study treatment or because they had received early alloHCT in aplasia. Of the remaining 302 patients, 97 underwent alloHCT and 149 received per protocol PR-CT, while 56 patients did not receive postremission therapy according to the respective study protocols due to early relapse, or adverse events. Since more time elapsed from CR1 in alloHCT patients compared with PR-CT patients (median no. of days 115 versus 78, P < 0.001), we compared the treatments in a time-dependent manner to avoid a time-selection bias. In multivariable analysis, OS of patients with alloHCT was significantly longer (HR 0.58, 95% CI 0.37-0.9, P¼0.02) compared with the PR-CT group. For RFS, the HR from the multivariable model comparing alloHCT and PR-CT was 0.51 (95% CI 0.34-0.76, P ¼ 0.001). The impact of alloHCT and PR-CT as time-dependent intervention is displayed in Simon-Makuch plots in Figure 2 .
Neither white blood count, lactate dehydrogenase, ECOG performance status at diagnosis nor AML type were significant predictors of RFS and OS in multivariable Cox regression analyses. Further, a significant impact of patient age on RFS, OS, CIR, and NRM was not observed. In interaction tests for a differential effect of alloHCT in different age groups, we did not find a significantly different impact of alloHCT on RFS in patients <40 years versus 40 years (interaction test, P ¼ 0.2). For OS, however, the results indicated that patients <40 years had a greater benefit from alloHCT than patients 40 years (P ¼ 0.07).
Outcomes after alloHCT or PR-CT
The probability of OS at 5 years was 66% (95% CI 57% to 76%) after alloHCT compared with 46% (95% CI 38% to 55%) after PR-CT ( Figure 2B ). The probability of RFS at 5 years from CR1 was 55% (95% CI 46% to 67%) for alloHCT patients and 31% (95% CI 24% to 39%) for PR-CT patients, respectively ( Figure  2A ). This improvement in RFS was due to a lower risk of relapse after alloHCT compared with PR-CT in CR1. Conditioning intensity had no significant impact on OS and RFS. The CIR at 5 years from CR1 was 23% (95% CI 15% to 32%) after alloHCT compared with 58% (95% CI 50% to 67%) after CT. The corresponding rates of NRM up to 5 years from CR1 were 20% (95% CI 12% to 28%) after alloHCT and 11% (95% CI 6% to 16%) after PR-CT (supplementary Figure S2 , available at Annals of Oncology online).
Discussion
In the absence of randomized controlled trials (RCTs) comparing the value of alloHCT to PR-CT, donor versus no-donor studies provide the best level of evidence. 'Biological assignment' (having an HLA-identical sibling at diagnosis or not) instead of randomization is used [19] under the assumption that his information is not linked to patient-or disease-related risk factors. These studies are more robust against bias, e.g. selection bias, as baseline information is used.
The present study demonstrates that patients with intermediate risk NPM1 mut-neg /CEBPA dm-neg /FLT3-ITD neg AML benefit from matched sibling alloHCT in CR1 in terms of RFS (HR 0.5, P ¼ 0.02) compared with PR-CT. Despite cross-over effects due to the option of HLA-compatible unrelated donor alloHCT in relapsed or refractory disease, a trend toward improved OS (HR 0.6, P ¼ 0.08) was also found.
In an intention-to-treat subgroup analysis, patients without sibling donor, who were randomized to the early transplant strategy, had a trend to better RFS and OS (HR 0.5, P ¼ 0.06 for both end points) compared with patients in the control arm. The difference between the two arms was the timing of HLAcompatible alloHCT, which was carried out earlier in the early alloHCT arm. When compared with the control arm, fewer patients in the early alloHCT arm received transplantation after experiencing relapse, although the overall rate of alloHCT in CR1 and in advanced stages was comparable.
We complemented these intention-to-transplant analyses with as-treated analyses, analyzing data from two subsequent RCTs and showed a significant improvement in OS (HR 0.58, P¼0.02) and RFS (HR 0.51, P ¼ 0.001) for patients who received alloHCT. Furthermore, we demonstrated a lower CIR after alloHCT (sup plementary Figure S1 , available at Annals of Oncology online). Notably, the OS benefit for alloHCT in CR1 could be demonstrated despite cross-over of 38% of patients in the PR-CT group who received alloHCT after relapse.
In the donor versus no-donor analysis published by Schlenk et al. [2] , the authors demonstrated a survival benefit for patients in the intermediate genetic risk group with either FLT3-ITD positive or NPM1 
FLT3-ITD
neg AML after alloHCT was better than that of patients with FLT3-ITD. Schmid et al. [10] reported 2-year OS after alloHCT of 75% in 290 patients with triple-negative AML, which is comparable to our results. A similar pattern of results with a better outcome in these patients was published by Ahn et al. [20] , reporting a 5-year OS of 61% for 27 patients. Preliminary data from another as-treated analysis have been presented by Esteve et al. [21] . They found that patients after alloHCT in CR1 had a better OS compared with patients with PR-CT (3-year OS 65% versus 49%).
Nevertheless, alloHCT is limited to physically fit patients with little comorbidity. For individual patients the risk of transplantationassociated morbidity and mortality has to be weighed against the chance to cure the underlying disease. Cornelissen et al. [22] proposed to integrate information derived from transplant-specific comorbidity scores and comprehensive transplant scores for individual decision making.
Except for the small subgroup of 15% of patients with intermediate risk NPM1 mut-neg /CEBPA dm-neg /FLT3-ITD neg AML and co-existing IDH1/2 mutations, no molecular targeted drugs are in development. The genetic heterogeneity of this subgroup of AMLs implies that drugable targets will not be identified in the near future [23] . Moreover, decision-making based on minimal residual disease (MRD) levels for the choice of the consolidation, as it is possible for NPM1 mut AML, will remain challenging and will require prospective validation. Whether or not patients with MRD-negative disease in CR1 benefit from alloHCT versus
